In a press release from 5/9, Seattle Children’s Hospital has announced results from a phase 1 pilot study showing “T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial remission.”
This pilot, the Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial opens the door for a PLAT-03 trial, where patients will receive “booster” infusions of a second T-cell product, called T antigen-presenting cells (T-APCs). The hope of the next pilot is to help put patients in long-term remission. Read more at: Seattle Children’s Hospital Website.
In a report today from HealthcareITNews, we hear about Carolinas HealthCare taking a new approach to treatment, taking a cue from Amazon.
CHS is attempting to anticipate new technologies that can be quickly adopted in hopes that it would help them become the ” de facto standard of care and experience”. In this way, CHS has begun a number of programs. For example, for $49 CHS provides “live, 24-hour access to medical providers via camera-enabled smartphones, tablets or computers.”
According to the report this “service alone doesn’t make Carolinas the Amazon Prime of healthcare — but it helps Carolinas move in that direction.” Read more at: http://www.healthcareitnews.com/news/carolinas-chases-dream-becoming-healthcares-amazon-prime
According to the University of Alabama at Birmingham Department of Surgery, physicians have transplanted a cadaver liver that was “kept alive” outside the body and tested for function for 24 hours before it was transplanted. According to the UAB website: “UAB’s School of Medicine and UAB Hospital have joined 14 other transplant centers in the United States in this study. Research efforts like this clinical trial have focused on overcoming the limitations of cold storage, which is the current universal standard for organ preservation, with a move toward normothermic machine perfusion.” Read more at: http://www.uab.edu/news/innovation/item/8226
According to NYU, infants who are not exposed to environmental stimulation show lower IQ’s in later years. Two students from the Tanson School of Engineering have come up with a solution. In an article from Engadget, today we find the Tot Bot, the brainchild of two NYU Tandon School of Engineering students. This touch-screen enabled wheelchair allows infants with disabilities to explore at will. Read more at Engadget.
Today we report on a device originally covered by Yanko Design back in November of 2016. The glucometer is a device about the size of a quarter and plugs directly into your mobile device. Developed by iHealth, the device, called Align, is now available for around $17 (not including the price of the glucose testing strips). Once made, the readings are transferred to an app and then to the IHealth Cloud. For those wondering, the iHealth website says the device is FDA approved. Read more at the iHealth website, here.
From an article on the PSFK website, we find a wearable that uses neurostimulation technology to reduce stress and improve sleep quality and mood. With, over 5,000 test sessions, and published studies on stress reduction, sleep quality, and mood, the Thync Relax Pro from Thync is now available for sale. This offering comes with a wearable device designed to encourage relaxation using low-level electrical stimulation and a smartphone app. Read more at PSFK or Thync .
You may have heard about The Precision Healthcare Initiative during 2015, but now the day is not far off in the future where such technologies as FHIR, HIE’s, biomedical informatics, and genomic data sharing will come together to create a new and better way of providing individualized healthcare. In an article from HealthcareITNews, they discuss a number of initiatives under way with the goal of realizing Precision Medicine. Read more at: http://www.healthcareitnews.com/news/dawn-precision-medicine-has-begun-onc-says